Drug Profile
ABC 1183
Alternative Names: ABC1183Latest Information Update: 27 Sep 2023
Price :
$50
*
At a glance
- Originator Apogee Biotechnology Corporation
- Class Anti-inflammatories; Antineoplastics; Thiazoles
- Mechanism of Action Cyclin dependent kinase 9 inhibitors; Glycogen synthase kinase 3 alpha inhibitors; Glycogen synthase kinase 3 beta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer; Inflammation
Most Recent Events
- 27 Sep 2023 Discontinued - Preclinical for Cancer in USA (PO)
- 27 Sep 2023 Discontinued - Preclinical for Inflammation in USA (PO)
- 28 Dec 2020 No recent reports of development identified for preclinical development in Cancer in USA (PO)